Di Federico A.; De Giglio A.; Sperandi F.; Melotti B.; Ardizzoni A.; Gelsomino F., Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinib, «ANTI-CANCER DRUGS», 2024, 35, pp. 86 - 88 [articolo]
Fabbri L.; Di Federico A.; Astore M.; Marchiori V.; Rejtano A.; Seminerio R.; Gelsomino F.; De Giglio A., From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC), «DIAGNOSTICS», 2024, 14, Article number: 48, pp. 1 - 29 [articolo]
De Giglio A.; Di Federico A.; Gariazzo E.; Metro G., Navigating challenges in EGFR exon 20 insertions: The PAPILLON trial unravels the promise of amivantamab-chemotherapy, «MED», 2024, 5, pp. 1 - 3 [articolo]
Li B.; Jia Z.; Huang Z.; Xue J.; Wang Y.; Guo C.; Si X.; Chen Z.; Li J.; Chen R.; Bie Z.; De Giglio A.; Christopoulos P.; Liang N.; Li S., Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report, «TRANSLATIONAL LUNG CANCER RESEARCH», 2023, 12, pp. 2322 - 2329 [articolo]Open Access
Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Prelaj A.; Lopez-Castro R.; Bosch-Barrera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar Nana F.; Ponce S.; Albarran-Artahona V.; Dal Maso A.; Spotti M.; Mielgo X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.B.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Mezquita L.; Planchard D., Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer, «CLINICAL LUNG CANCER», 2023, 000, pp. 1 - 11 [articolo]
De Giglio A.; Deiana C.; Di Federico A., Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients, «JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY», 2023, 149, pp. 1835 - 1847 [articolo]
Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, Rita; Potena, Luciano, Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians, «DRUG SAFETY», 2023, 46, pp. 819 - 833 [articolo]Open Access
Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A., Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review, «LUNG CANCER: TARGETS AND THERAPY», 2023, 14, pp. 11 - 25 [articolo]
Mosca M.; Nigro M.C.; Pagani R.; De Giglio A.; Di Federico A., Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond, «BIOMOLECULES», 2023, 13, Article number: 1803, pp. 1 - 15 [articolo]
Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lamberti G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M., Peripheral nervous system adverse events associated with immune checkpoint inhibitors, «JOURNAL OF NEUROLOGY», 2023, 270, pp. 2975 - 2986 [articolo]Open Access
Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea, Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis, «JOURNAL OF THE NATIONAL CANCER INSTITUTE», 2023, 115, pp. 29 - 42 [articolo]
Di Federico A.; Ricciotti I.; Favorito V.; Michelina S.V.; Scaparone P.; Metro G.; De Giglio A.; Pecci F.; Lamberti G.; Ambrogio C.; Ricciuti B., Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer, «CURRENT ONCOLOGY REPORTS», 2023, 25, pp. 1017 - 1029 [articolo]
De Giglio A.; Ricciuti B.; Metro G., The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks, «DRUGS IN CONTEXT», 2023, 12, Article number: 2022-11-4, pp. 1 - 3 [articolo]Open Access
Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.; Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G., Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease, «DRUGS IN CONTEXT», 2022, 11, Article number: A1, pp. 1 - 10 [articolo]
De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G., Advanced non-small-cell lung cancer: how to manage non-oncogene disease, «DRUGS IN CONTEXT», 2022, 11, Article number: 2022-2-4, pp. 1 - 14 [articolo]Open Access
